AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7743989 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer duration of diarrhoea before inclusion
Number of subjects: 150
Study 2337005 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric consultation team (GCT) intervention with follow-up after discharge
Number of subjects: 132
Study 430238 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 g nitrogen per day
Number of subjects: 6
Study 430238 — intervention group
Group type: COMPARATOR
Intervention: 12 g nitrogen per day
Number of subjects: 6
Study 30840141 — intervention group
Group type: EXPERIMENTAL
Intervention: EXCIMER laser-assisted trephination
Number of subjects: 68
Study 30840141 — intervention group
Group type: COMPARATOR
Intervention: FEMTO laser-assisted trephination
Number of subjects: 68
Study 28899589 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexor Carpi Radialis (FCR) tendon
Number of subjects: 60
Study 28899589 — intervention group
Group type: COMPARATOR
Intervention: Allograft
Number of subjects: 60
Study 26277887 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone 15 mg once daily
Number of subjects: 100
Study 26277887 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone 30 mg once daily
Number of subjects: 100
Study 26277887 — intervention group
Group type: COMPARATOR
Intervention: alogliptin 25 mg once daily (control)
Number of subjects: 100
Study 22832022 — intervention group
Group type: EXPERIMENTAL
Intervention: system support
Number of subjects: 60
Study 22832022 — intervention group
Group type: EXPERIMENTAL
Intervention: list support
Number of subjects: 60
Study 22832022 — intervention group
Group type: COMPARATOR
Intervention: no memory support
Number of subjects: 60
Study 21775563 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (2.7 g long-chain n-3 fatty acids daily during the third trimester)
Number of subjects: 533
Study 21775563 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control group)
Number of subjects: 533
Study 21775563 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical measures (insulin, glucose, glycated hemoglobin, leptin, adiponectin, insulin-like growth factor I, high-sensitivity C-reactive protein)
Number of subjects: 533
Study 19957549 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin 3.6 mg once every 4 weeks for 12 weeks (Group A)
Number of subjects: 28
Study 19957549 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin with 1/2 piece of estradiol patch weekly and 6 mg oral medroxyprogesterone acetate daily for 12 weeks (Group B)
Number of subjects: 28
Study 17604961 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler echocardiography/SR imaging at rest and during bicycle exercise at 1 and 2 W/kg
Number of subjects: 24
Study 17604961 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 24
Study 15386934 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐Hesperidin at 100 or 500 mg/d for 6 weeks
Number of subjects: 0
Study 11496020 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (6 weeks open-label treatment followed by 6 weeks double-blind treatment)
Number of subjects: 15
Study 11496020 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 weeks double-blind treatment)
Number of subjects: 15
Study 9771234 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-latex surgical gloves
Number of subjects: 4
Study 9771234 — intervention group
Group type: COMPARATOR
Intervention: Latex surgical gloves
Number of subjects: 4
Study 7796388 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysosomal arylsulphatase A activity in leukocytes from patients with acute leukemia
Number of subjects: 0
Study 7796388 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 0
Study 2205182 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% topical apraclonidine hydrochloride
Number of subjects: 20
Study 2205182 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% topical apraclonidine hydrochloride
Number of subjects: 20
Study 2205182 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate
Number of subjects: 20
Study 2205182 — intervention group
Group type: COMPARATOR
Intervention: Placebo (implied control)
Number of subjects: 20
Study 71971 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 150 mg twice daily (morning and evening) plus placebo at mid-day
Number of subjects: 30
Study 71971 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen 100 mg three times daily
Number of subjects: 30
Study 71971 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (both regimens)
Number of subjects: 30
Study 71971 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen 150 mg twice daily
Number of subjects: 30
Study 31590930 — intervention group
Group type: EXPERIMENTAL
Intervention: SDAI remission
Number of subjects: 0
Study 31590930 — intervention group
Group type: EXPERIMENTAL
Intervention: CDAI remission
Number of subjects: 0
Study 31590930 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS28(CRP) remission
Number of subjects: 0
Study 31590930 — intervention group
Group type: COMPARATOR
Intervention: SDAI or CDAI remission but not Boolean remission
Number of subjects: 0
Study 31590930 — intervention group
Group type: COMPARATOR
Intervention: DAS28(CRP) remission but not Boolean remission
Number of subjects: 0
Study 31135088 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 30
Study 31135088 — intervention group
Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA
Number of subjects: 30
Study 27712924 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone administration for 48h
Number of subjects: 41
Study 27712924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 26424549 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy intensification plus HIV DNA prime and rAd5 boost vaccine
Number of subjects: 28
Study 26424549 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral therapy intensification alone
Number of subjects: 28
Study 23625478 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 210
Study 23625478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 22174164 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 IU vitamin D3
Number of subjects: 102
Study 22174164 — intervention group
Group type: EXPERIMENTAL
Intervention: 100,000 IU vitamin D3
Number of subjects: 102
Study 22174164 — intervention group
Group type: COMPARATOR
Intervention: Control group (vitamin E)
Number of subjects: 102
Study 18824930 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 20
Study 18824930 — intervention group
Group type: COMPARATOR
Intervention: Cycling ergometry (CYL)
Number of subjects: 20
Study 15897791 — intervention group
Group type: EXPERIMENTAL
Intervention: EDUC + FPI
Number of subjects: 61
Study 15897791 — intervention group
Group type: COMPARATOR
Intervention: EDUC
Number of subjects: 61
Study 12849767 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous rapid naming tasks (digit and color naming)
Number of subjects: 40
Study 12849767 — intervention group
Group type: EXPERIMENTAL
Intervention: Balancing problems (assessed singly and with a secondary task)
Number of subjects: 40
Study 10199338 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (400 mg 3 times daily)
Number of subjects: 16
Study 10199338 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg 3 times daily)
Number of subjects: 16
Study 10199338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7710444 — intervention group
Group type: COMPARATOR
Intervention: 0.5-20 mg intravenous pancopride
Number of subjects: 40
Study 7710444 — intervention group
Group type: COMPARATOR
Intervention: 5-40 mg oral solution of pancopride
Number of subjects: 40
Study 7710444 — intervention group
Group type: COMPARATOR
Intervention: 20 mg intravenous infusion, oral tablet and oral solution
Number of subjects: 40
Study 1693030 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 22
Study 1693030 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 22
Study 7008978 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical benzydamine (10/00)
Number of subjects: 124
Study 7008978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 12195253 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented all-polyethylene glenoid component
Number of subjects: 39
Study 12195253 — intervention group
Group type: COMPARATOR
Intervention: Cementless metal-backed glenoid component
Number of subjects: 39
Study 31394243 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Repair (EVAR)
Number of subjects: 70
Study 31394243 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical management
Number of subjects: 70
Study 29855100 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (thin mucosal tissue)
Number of subjects: 55
Study 29855100 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (medium mucosal tissue)
Number of subjects: 55
Study 29855100 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (thick mucosal tissue)
Number of subjects: 55
Study 26678611 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive game-based balance training including repetitive weight shifting and virtual obstacle crossing tasks
Number of subjects: 22
Study 26678611 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) received no exercise intervention and continued their normal activity
Number of subjects: 22
Study 24814934 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood
Number of subjects: 0
Study 24814934 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood
Number of subjects: 0
Study 23327032 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg hyperbaric bupivacaine 0.5%
Number of subjects: 80
Study 23327032 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg hyperbaric bupivacaine 0.5%
Number of subjects: 80
Study 23327032 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg hyperbaric bupivacaine 0.5%
Number of subjects: 80
Study 23327032 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg hyperbaric bupivacaine 0.5%
Number of subjects: 80
Study 20159310 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI-545 (0.3-30.0 mg/kg)
Number of subjects: 36
Study 20159310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 17610061 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Triple P-Positive Parenting Program
Number of subjects: 139
Study 17610061 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Triple P-Positive Parenting Program
Number of subjects: 139
Study 17610061 — intervention group
Group type: EXPERIMENTAL
Intervention: Self Directed Triple P-Positive Parenting Program
Number of subjects: 139
Study 17610061 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced, Standard, and Self Directed Triple P-Positive Parenting Programs
Number of subjects: 139
Study 17610061 — intervention group
Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 139
Study 15609026 — intervention group
Group type: EXPERIMENTAL
Intervention: Water + Cur
Number of subjects: 6
Study 15609026 — intervention group
Group type: EXPERIMENTAL
Intervention: Water - Cur
Number of subjects: 6
Study 15609026 — intervention group
Group type: COMPARATOR
Intervention: Dry Land (DL)
Number of subjects: 6
Study 12047494 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine monotherapy 5-20 mg/day
Number of subjects: 0
Study 12047494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10442363 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant UFT (400 mg/day for 12 months)
Number of subjects: 139
Study 10442363 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 139
Study 10442363 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 139
Study 10442363 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 139
Study 8578802 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphtheria/Tetanus/Pertussis (DTP) vaccine
Number of subjects: 190
Study 8578802 — intervention group
Group type: COMPARATOR
Intervention: Diphtheria/Tetanus (DT) vaccine
Number of subjects: 190
Study 2190540 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral low dose cyclophosphamide
Number of subjects: 0
Study 2190540 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous high dose cyclophosphamide
Number of subjects: 0
Study 2190540 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo treatment
Number of subjects: 0
Study 2190540 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose cyclophosphamide
Number of subjects: 0
Study 2190540 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose cyclophosphamide
Number of subjects: 0
Study 2190540 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (both doses)
Number of subjects: 0
Study 378731 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting formulation of propranolol ('Inderal' LA) given once daily
Number of subjects: 29
Study 378731 — intervention group
Group type: COMPARATOR
Intervention: Conventional propranolol tablets given twice daily
Number of subjects: 29
Study 30640148 — intervention group
Group type: COMPARATOR
Intervention: Cued Self-Monitoring (TRACK)
Number of subjects: 149
Study 30640148 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of BCTs (COMBO)
Number of subjects: 149
Study 30640148 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking Intentions Feedback (PLAN)
Number of subjects: 149
Study 30640148 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking Performance Feedback (USE)
Number of subjects: 149
Study 30640148 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Goal Support (GOAL)
Number of subjects: 149
Study 30640148 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessments (EMA)
Number of subjects: 149
Study 29096631 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable logistic regression model including sociodemographic, clinical and biochemical factors
Number of subjects: 1409
Study 29096631 — intervention group
Group type: EXPERIMENTAL
Intervention: Simpler model including clinical factors only (no biomarkers)
Number of subjects: 1409
Study 29096631 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing predicted risk of uncomplicated pregnancy and birth
Number of subjects: 1409
Study 24652539 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin mix (dexamethasone and lignocaine)
Number of subjects: 0
Study 24652539 — intervention group
Group type: COMPARATOR
Intervention: 2% lignocaine with 1:200,000 epinephrine
Number of subjects: 0
Study 23877691 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-5885 1 mg once daily
Number of subjects: 10
Study 23877691 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-5885 ≥3 mg once daily
Number of subjects: 10
Study 23877691 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-5885 30 mg and 90 mg once daily
Number of subjects: 10
Study 23877691 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-5885
Number of subjects: 10
Study 20309694 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide (CyP) (500 mg/m² of body surface monthly) and antioxidants (alpha-tocopherol 400 IU/day and ascorbic acid 1,000 mg/day)
Number of subjects: 13
Study 20309694 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (CyP) only
Number of subjects: 13
Study 18280789 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 180
Study 16464962 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of paracetamol and ibuprofen
Number of subjects: 0
Study 16464962 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 12957421 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium (GIK) infusion for 8 to 12 hours
Number of subjects: 940
Study 12957421 — intervention group
Group type: COMPARATOR
Intervention: Control group (no infusion)
Number of subjects: 940
Study 10830661 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstruction of the anterior talo-fibular ligament using a semi-tendinosis free graft
Number of subjects: 26
Study 8891888 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric, reduced fat (< 30%) low‐cholesterol diet with placebo
Number of subjects: 20
Study 8891888 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric, reduced fat (< 30%) low‐cholesterol diet with pravastatin (40 mg/day)
Number of subjects: 20
Study 8891888 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 normocholesterolemic healthy subjects)
Number of subjects: 20
Study 8891888 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (diet with pravastatin and diet with placebo)
Number of subjects: 20
Study 1992396 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia
Number of subjects: 88
Study 1992396 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural infusion
Number of subjects: 88
Study 6603074 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercises consisting of gymnastics and walking according to the interval principle (twice a week), sauna visits twice a week, diadynamic series of the current.
Number of subjects: 0
Study 6603074 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking group (specific details not provided)
Number of subjects: 0
Study 6603074 — intervention group
Group type: EXPERIMENTAL
Intervention: Sauna group (specific details not provided)
Number of subjects: 0
Study 6603074 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval walking (specific details not provided)
Number of subjects: 0
Study 31101732 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified adductor canal (SAC) block
Number of subjects: 40
Study 31101732 — intervention group
Group type: COMPARATOR
Intervention: Adductor canal block (ACB)
Number of subjects: 40
Study 31101732 — intervention group
Group type: EXPERIMENTAL
Intervention: SAC block
Number of subjects: 40
Study 28816281 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous flurbiprofen axetil (1 mg/kg) 1 hour before the procedure
Number of subjects: 81
Study 28816281 — intervention group
Group type: COMPARATOR
Intervention: Intrarectal 5% lidocaine gel (60 mg) 5 minutes before the procedure
Number of subjects: 81
Study 28816281 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal 5% lidocaine gel (60 mg) 5 minutes before the procedure and intravenous flurbiprofen axetil (1 mg/kg) 1 hour before the procedure
Number of subjects: 81
Study 25233242 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal medicine
Number of subjects: 146
Study 25233242 — intervention group
Group type: COMPARATOR
Intervention: Psychotropic medications
Number of subjects: 146
Study 23752495 — intervention group
Group type: EXPERIMENTAL
Intervention: NSP-enriched diet (42 g NSP, 2.5 g RS)
Number of subjects: 14
Study 23752495 — intervention group
Group type: EXPERIMENTAL
Intervention: RS-enriched diet (16 g NSP, 25 g RS)
Number of subjects: 14
Study 23752495 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss diet (30% calories, 8 MJ/day)
Number of subjects: 14
Study 23752495 — intervention group
Group type: COMPARATOR
Intervention: Energy-maintenance diet (27 g NSP and 5 g RS)
Number of subjects: 14
Study 22052140 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 74
Study 22052140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 19361582 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-Intermittent Anal Dilatation (CIAD)
Number of subjects: 40
Study 19361582 — intervention group
Group type: COMPARATOR
Intervention: Lateral Internal Sphincterotomy (LIS)
Number of subjects: 40
Study 16126804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular gentamicin 5 mg/kg/day once-daily (OD)
Number of subjects: 310
Study 16126804 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular gentamicin 5 mg/kg/day thrice-daily (TD)
Number of subjects: 310
Study 15071015 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured treatment interruptions (STIs)
Number of subjects: 51
Study 15071015 — intervention group
Group type: COMPARATOR
Intervention: No structured treatment interruptions (Control)
Number of subjects: 51
Study 11053508 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 136
Study 11053508 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vitamin A and iron supplementation
Number of subjects: 136
Study 11053508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 9564977 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 336 microg/day by metered dose inhaler (MDI)
Number of subjects: 328
Study 9564977 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA) 800 microg/day by MDI with a built-in tube extender
Number of subjects: 328
Study 9564977 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP)
Number of subjects: 328
Study 9564977 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA)
Number of subjects: 328
Study 9564977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study 8044782 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (CPT‐11) administered at dose levels ranging from 50 to 145 mg/m2 (30‐90 min i.v. infusion)
Number of subjects: 59
Study 8044782 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (CPT‐11)
Number of subjects: 59
Study 3051962 — intervention group
Group type: EXPERIMENTAL
Intervention: Golytely-RSS plus oral bisacodyl
Number of subjects: 100
Study 3051962 — intervention group
Group type: COMPARATOR
Intervention: Standard 1-day diet/cathartic method
Number of subjects: 100
Study 3051962 — intervention group
Group type: EXPERIMENTAL
Intervention: Golytely-RSS
Number of subjects: 100
Study 3051962 — intervention group
Group type: COMPARATOR
Intervention: Standard preparation
Number of subjects: 100
Study 29561461 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led educational intervention
Number of subjects: 80
Study 29561461 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 80